NANG KUANG (1752) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 南光

NANG KUANG (1752) reported revenue of NT$200.2 million for Oct 2026, +6.6% year on year and +23.5% from the previous month. Revenue for Jan–Oct 2026 was NT$1.77 billion (-3.3% year on year).

In Oct 2026, it ranked No. 41 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$216 million24/10Nov 2024 NT$165.1 millionDec 2024 NT$198.1 millionJan 2025 NT$195.8 millionFeb 2025 NT$195.1 million25/02Mar 2025 NT$188.6 millionApr 2025 NT$178.6 millionMay 2025 NT$173.8 millionJun 2025 NT$189.3 million25/06Jul 2025 NT$183.9 millionAug 2025 NT$150.6 millionSep 2025 NT$189.4 millionOct 2025 NT$187.8 million25/10Nov 2025 NT$152.4 millionDec 2025 NT$177 millionJan 2026 NT$211.8 millionFeb 2026 NT$156 million26/02Mar 2026 NT$161.8 millionApr 2026 NT$196.7 millionMay 2026 NT$186.8 millionJun 2026 NT$155.1 million26/06Jul 2026 NT$171.8 millionAug 2026 NT$169.2 millionSep 2026 NT$162.1 millionOct 2026 NT$200.2 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$200.2 million+6.6%+23.5%
Sep 2026NT$162.1 million-14.4%-4.2%
Aug 2026NT$169.2 million+12.4%-1.6%
Jul 2026NT$171.8 million-6.6%+10.8%
Jun 2026NT$155.1 million-18.1%-17.0%
May 2026NT$186.8 million+7.5%-5.1%
Apr 2026NT$196.7 million+10.2%+21.6%
Mar 2026NT$161.8 million-14.2%+3.7%
Feb 2026NT$156 million-20.0%-26.4%
Jan 2026NT$211.8 million+8.2%+19.7%
Dec 2025NT$177 million-10.6%+16.2%
Nov 2025NT$152.4 million-7.7%-18.8%
Oct 2025NT$187.8 million-13.1%-0.8%
Sep 2025NT$189.4 million+0.3%+25.8%
Aug 2025NT$150.6 million-18.8%-18.1%
Jul 2025NT$183.9 million-10.7%-2.8%
Jun 2025NT$189.3 million+19.1%+8.9%
May 2025NT$173.8 million-9.7%-2.7%
Apr 2025NT$178.6 million+11.0%-5.3%
Mar 2025NT$188.6 million+12.3%-3.4%
Feb 2025NT$195.1 million+42.7%-0.4%
Jan 2025NT$195.8 million-12.5%-1.1%
Dec 2024NT$198.1 million+41.5%+19.9%
Nov 2024NT$165.1 million-6.2%-23.5%
Oct 2024NT$216 million+7.9%+14.4%

Jan–Oct 2026 cumulative: NT$1.77 billion (-3.3% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: NANG KUANG vs PEC / NANG KUANG vs Lotus Pharm / NANG KUANG vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16